HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes

Journal of Virology

Volumn 86, Issue 7, 2012, Pages 3574-3587

  Tong, Tommy ^a   Crooks, Ema T ^a   Osawa, Keiko ^a   Binley, James M ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN G2; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIGEN BINDING; ANTIGENICITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CROSS REACTION; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR RECOGNITION; PRIORITY JOURNAL; VIRUS INFECTIVITY; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION;

ANTIBODIES, NEUTRALIZING; CELL LINE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; PROTEIN MULTIMERIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84861324362     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06938-11     Document Type: Article

References (72)

1. Agrawal N, et al. 2011. Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1). PLoS One 6:e21339.
2. Alam SM, et al. 2007. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 178:4424-4435.
3. Binley J. June 2010. Enzymatic methods to produce pure native authentic HIV-1 Env trimer immunogens. US patent 61/360,067.
4. Binley JM. 2009. Specificities of broadly neutralizing anti-HIV-1 sera. Curr. Opin. HIV AIDS 4:364-372.
5. Binley JM, et al. 2003. Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J. Virol. 77:5678-5684.
6. Binley JM, et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651-11668.
7. Binley JM, et al. 2002. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 76:2606-2616.
8. Bonomelli C, et al. 2011. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One 6:e23521.
9. Bonsignori M, et al. 2011. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85:9998-10009.
10. Burton DR, et al. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024-1027.
11. Calarese DA, et al. 2003. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300:2065-2071.
12. Center RJ, et al. 2002. Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface. J. Virol. 76: 7863-7867.
13. Chen X, et al. 2005. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses. J. Virol. 79:5537-5547.
14. Chertova E, et al. 2002. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 76:5315-5325.
15. Corti D, et al. 2010. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5:e8805.
16. Crooks ET, et al. 2008. Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization. Virology 377:364-378.
17. Crooks ET, et al. 2007. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 366:245-262.
18. Crooks ET, et al. 2005. Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum. Antibodies 14:101-113.
19. Crooks ET, Tong T, Osawa K, Binley JM. 2011. Enzyme digests eliminate nonfunctional env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected. J. Virol. 85:5825-5839.
20. Dewar RL, Vasudevachari MB, Natarajan V, Salzman NP. 1989. Biosynthesis and processing of human immunodeficiency virus type 1 envelope glycoproteins: effects of monensin on glycosylation and transport. J. Virol. 63:2452-2456.
21. Doores KJ, Burton DR. 2010. Variable loop glycan dependency of the broad and potent HIV-1 neutralizing antibodies PG9 and PG16. J. Virol. 84:10510-10521.
22. Doria-Rose NA, et al. 2010. Breadth of human immunodeficiency virusspecific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84:1631-1636.
23. Earl PL, Moss B, Doms RW. 1991. Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J. Virol. 65:2047-2055.
24. Edinger AL, et al. 2000. Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein. J. Virol. 74:7922-7935.
25. Edwards TG, et al. 2002. Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J. Virol. 76:2683-2691.
26. Fouts TR, Binley JM, Trkola A, Robinson JE, Moore JP. 1997. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71:2779-2785.
27. Hammonds J, et al. 2005. Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. J. Virol. 79:14804-14814.
28. Hammonds J, Chen X, Zhang X, Lee F, Spearman P. 2007. Advances in methods for the production, purification, and characterization of HIV-1 Gag-Env pseudovirion vaccines. Vaccine 25:8036-8048.
29. Haynes BF, et al. 2005. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308:1906-1908.
30. Haynes BF, Montefiori DC. 2006. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccines 5:347-363.
31. Hicar MD, et al. 2010. Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV. J. Acquir. Immune Defic. Syndr. 54: 223-235.
32. Hoxie JA. 2010. Toward an antibody-based HIV-1 vaccine. Annu. Rev. Med. 61:135-152.
33. Joyner AS, Willis JR, Crowe JE, Jr, Aiken C. 2011. Maturation-induced cloaking of neutralization epitopes on HIV-1 particles. PLoS pathogens 7:e1002234.
34. Kang YK, et al. 2009. Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine 27: 5120-5132.
35. LaCasse RA, et al. 1999. Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science 283:357-362.
36. Land A, Zonneveld D, Braakman I. 2003. Folding of HIV-1 envelope glycoprotein involves extensive isomerization of disulfide bonds and conformation-dependent leader peptide cleavage. FASEB J. 17:1058-1067.
37. Leaman DP, Kinkead H, Zwick MB. 2010. In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1. J. Virol. 84:3382-3395.
38. Li M, et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125.
39. Li M, et al. 2006. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 80:11776-11790.
40. Li Y, et al. 1996. Effects of inefficient cleavage of the signal sequence of HIV-1 gp 120 on its association with calnexin, folding, and intracellular transport. Proc. Natl. Acad. Sci. U. S. A. 93:9606-9611.
41. Liao Z, Graham DR, Hildreth JE. 2003. Lipid rafts and HIV pathogenesis: virion-associated cholesterol is required for fusion and infection of susceptible cells. AIDS Res. Hum. Retroviruses 19:675-687.
42. Mascola JR, Montefiori DC. 2010. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28:413-444.
43. Means RE, Desrosiers RC. 2000. Resistance of native, oligomeric envelope on simian immunodeficiency virus to digestion by glycosidases. J. Virol. 74:11181-11190.
44. Moore PL, et al. 2006. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 80:2515-2528.
45. Murakami T, Freed EO. 2000. The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. Proc. Natl. Acad. Sci. U. S. A. 97:343-348.
46. Nelson JD, et al. 2007. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J. Virol. 81:4033-4043.
47. Nyambi PN, et al. 1998. Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J. Virol. 72:9384-9391.
48. Pancera M, Wyatt R. 2005. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 332:145-156.
49. Pantophlet R, Aguilar-Sino RO, Wrin T, Cavacini LA, Burton DR. 2007. Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology 364:441-453.
50. Pejchal R, et al. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334:1097-1103.
51. Perez LG, Costa MR, Todd CA, Haynes BF, Montefiori DC. 2009. Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membraneproximal external region of gp41. J. Virol. 83:7397-7410.
52. Phogat S, Wyatt RT, Karlsson Hedestam GB. 2007. Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets. J. Intern. Med. 262:26-43.
53. Poignard P, et al. 2003. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J. Virol. 77: 353-365.
54. Poon B, et al. 2005. Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1. J. Virol. 79:4927-4935.
55. Roben P, et al. 1994. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J. Virol. 68:4821-4828.
56. Sanders RW, et al. 2002. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76:7293-7305.
57. Sather DN, et al. 2009. Factors associated with the development of crossreactive neutralizing antibodies during HIV-1 infection. J. Virol. 83:757-769.
58. Scanlan CN, et al. 2002. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of _1¡2 mannose residues on the outer face of gp120. J. Virol. 76:7306-7321.
59. Scheid JF, et al. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633-1637.
60. Scherer EM, Leaman DP, Zwick MB, McMichael AJ, Burton DR. 2010. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc. Natl. Acad. Sci. U. S. A. 107:1529-1534.
61. Schulke N, et al. 2002. Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J. Virol. 76:7760-7776.
62. Sun ZY, et al. 2008. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 28:52-63.
63. Vaine M, et al. 2008. Improved induction of antibodies against key neutralizing epitopes by HIV-1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J. Virol. 82:7369-7378.
64. Vzorov AN, Lea-Fox D, Compans RW. 1999. Immunogenicity of full length and truncated SIV envelope proteins. Viral Immunol. 12:205-215.
65. Walker LM, Burton DR. 2010. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 22:358-366.
66. Walker LM, et al. 2010. High throughput functional screening of activated B cells from 4 African elite neutralizers yields a panel of novel broadly neutralizing antibodies, abstr OA10.06 LB. AIDS Vaccine 2010 Conf.
67. Walker LM, et al. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470.
68. Walker LM, et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
69. Willey RL, Bonifacino JS, Potts BJ, Martin MA, Klausner RD. 1988. Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc. Natl. Acad. Sci. U. S. A. 85: 9580-9584.
70. Wu X, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861.
71. Xiang SH, Doka N, Choudhary RK, Sodroski J, Robinson JE. 2002. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res. Hum. Retroviruses 18:1207-1217.
72. Zwick MB, Saphire EO, Burton DR. 2004. gp41: HIV's shy protein. Nat. Med. 10:133-134.